Pfizer Inc.

Pfizer discovers, develops, and commercializes prescription medicines and vaccines across therapeutic areas including oncology, inflammation, cardiovascular disease, and infectious diseases. Key revenue drivers include cancer drugs (Ibrance, Xtandi), anticoagulants (Eliquis), vaccines (Prevnar for pneumonia), and migraine treatments (Nurtec). The company operates through branded pharmaceutical sales to global markets, with a traditional pharma business model focused on patent-protected medicines.

Pfizer faces significant headwinds as COVID-19 product revenues decline from pandemic peaks, with the stock trading at low P/E multiples reflecting patent expirations and generic competition. The company is investing heavily in oncology acquisitions like Seagen to rebuild growth. Strengths include cash flow generation, dividend reliability, and a diverse therapeutic portfolio. Risks include continued COVID revenue erosion, integration execution for acquisitions, patent cliffs on major products, and pricing pressure from government negotiations. The business requires constant pipeline renewal.

In oncology, Bristol Myers Squibb, Merck, Roche, and AstraZeneca compete for cancer treatment market share. Johnson & Johnson and Eli Lilly compete across multiple therapeutic areas. For cardiovascular drugs like Eliquis, Bristol Myers Squibb is a partner but also a competitor with other products. In vaccines, Merck (Gardasil), Sanofi, and GSK compete for immunization markets. Moderna competes in mRNA platforms.

Pfizer has paid uninterrupted quarterly dividends for decades and maintained them even as COVID revenues declined, demonstrating commitment to shareholder income. The company targets a sustainable payout ratio and has historically increased dividends over time, though growth rates vary with patent cycles and acquisition activity. Despite current business challenges, Pfizer preserved its dividend through the post-pandemic transition, prioritizing cash returns alongside investments in oncology and other growth areas.

PFE last closed at $27.72, up 0.25% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $23.58 and a high of $29.21. The current price represents 74% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Among 36 analysts covering PFE, the consensus rating is Hold — 14 rate it a buy, 20 hold, and 2 sell. The average price target sits at $33.90, implying 22% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Pfizer Inc. generated $61.87B in revenue during fiscal year 2026, with $7.68B reaching the bottom line as net income. The net profit margin of 12.4% is solid for its sector.

PFE trades at a P/E ratio of 36.13 on trailing earnings of $0.76 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Pharmaceuticals sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: +15.64% (1Y), +10.09% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether PFE is outperforming or lagging the broader market.